Immunoglobulin A in serum: an old acquaintance as a new prognostic biomarker in idiopathic pulmonary fibrosis. (8th June 2015)

• Record Type: Journal Article
• Authors: ten Klooster, L.; van Moorsel, C. H. M.; Kwakkel‐van Erp, J. M.; van Velzen‐Blad, H.; Grutters, J. C.
• Is Part Of: Clinical and experimental immunology. Volume 181:Number 2(2015:Aug.)
• Page Start: 357
• Page End: 361
• Publication Date: 2015-06-08
• Subjects: Immunopathology -- Periodicals; 616.079
• DOI: 10.1111/cei.12636
• Languages: English
• ISSNs: 0009-9104

Abstract

<abstract abstract-type="main"> <title>Summary</title> <p>Immunoglobulin (Ig)A is an important immunoglobulin in mucosal immunity and protects the lungs against invading pathogens. The production of IgA is regulated by transforming growth factor (TGF)‐β, a versatile cytokine and key player in the pathogenesis of pulmonary fibrosis. TGF‐β is up‐regulated in patients with idiopathic pulmonary fibrosis (IPF), but difficult to use as a biomarker. The aim of this study was to evaluate the prognostic value of IgA in serum in patients with IPF. We examined IgA levels at time of diagnosis in 86 patients diagnosed with IPF. Mean serum IgA level in IPF is 3·22 g/l and regression analyses showed a significant association with mortality (hazard ratio = 1·445, <italic>P =</italic> 0·002). A significantly worse survival was found in patients with IgA serum levels &gt; 2·85 g/l compared to patients with lower IgA serum levels (<italic>P</italic> = 0·003). These findings were confirmed in a duplication cohort. In conclusion, the level of IgA in blood is a promising prognostic marker in IPF and can be implemented easily in the hospital setting. Future studies are warranted to investigate if repeated measurements of serum IgA can further improve the performance of serum IgA as a prognostic marker.</p> </abstract>